2.3(top 20%)
impact factor
1.2K(top 20%)
papers
18.4K(top 10%)
citations
55(top 10%)
h-index
2.4(top 20%)
extended IF
1.3K
all documents
20.3K
doc citations
85(top 10%)
g-index

Top Articles

#TitleJournalYearCitations
1Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteriaAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration2017607
2Screening for cognition and behaviour changes in ALSAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration2014421
3A revision of the El Escorial criteria - 2015Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration2015373
4Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patientsAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration2014293
5Bulbar and speech motor assessment in ALS: Challenges and future directionsAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration2013166
6Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS)Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration2014157
7Deciphering amyotrophic lateral sclerosis: What phenotype, neuropathology and genetics are telling us about pathogenesisAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration2013142
8Premorbid body mass index and risk of amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration2013138
9Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): A cognitive tool for motor disordersAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration2015138
10Mechanisms, models and biomarkers in amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration2013135
11Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trialAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration2020133
12Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseasesAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration2014131
13The validation of the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS)Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration2016125
14Eye tracking communication devices in amyotrophic lateral sclerosis: Impact on disability and quality of lifeAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration2013123
15Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating ScaleAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration2014111
16The Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen: A cross-sectional comparison of established screening tools in a German-Swiss populationAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration2015109
17Brain-computer interface (BCI) evaluation in people with amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration2014100
18Involvement of spinal sensory pathway in ALS and specificity of cord atrophy to lower motor neuron degenerationAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201396
19The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trialsAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201388
20Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimicsAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201485
21Emotional empathy in amyotrophic lateral sclerosis: a behavioural and voxel-based morphometry studyAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201485
22Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALSAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201684
23Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201382
24Longitudinal structural changes in ALS: a three time-point imaging study of white and gray matter degenerationAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201882
25Identification of RNA bound to the TDP-43 ribonucleoprotein complex in the adult mouse brainAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201377
26Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patientsAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201576
27Neurofilaments in pre-symptomatic ALS and the impact of genotypeAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201976
28High-caloric food supplements in the treatment of amyotrophic lateral sclerosis: A prospective interventional studyAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201375
29The involvement of the cerebellum in amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201375
30Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutationsAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201575
31Is exposure to cyanobacteria an environmental risk factor for amyotrophic lateral sclerosis and other neurodegenerative diseases?Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration201372
32Prognostic value of efficiently correcting nocturnal desaturations after one month of non-invasive ventilation in amyotrophic lateral sclerosis: A retrospective monocentre observational cohort studyAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201371
33The natural history of motor neuron disease: Assessing the impact of specialist careAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201370
34The El Escorial criteria: Strengths and weaknessesAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201569
35Primary lateral sclerosis: a distinct entity or part of the ALS spectrum?Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration201969
36Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALSAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201368
37Incorporation of telehealth into a multidisciplinary ALS Clinic: feasibility and acceptabilityAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201767
38Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration202066
39Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementiaAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201565
40Mind the gap: The mismatch between clinical and imaging metrics in ALSAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201565
41The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onsetAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201665
42Eye-tracking in amyotrophic lateral sclerosis: A longitudinal study of saccadic and cognitive tasksAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201665
43Identifying behavioural changes in ALS: Validation of the Beaumont Behavioural Inventory (BBI)Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration201764
44pNfH is a promising biomarker for ALSAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201363
45Attitudes towards hastened death in ALS: A prospective study of patients and family caregiversAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201463
46Neuroimaging patterns along the ALS-FTD spectrum: a multiparametric imaging studyAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201763
47Screening for cognitive dysfunction in ALS: validation of the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) using age and education adjusted normative dataAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201763
48Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-netAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201763
49Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trialAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201963
50Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration201462